By using our website, you are agreeing to cookies being stored and Google Analytics being used on your device in order to offer the best possible service. You can find more information on thishere.
Austria.
Where Your Profits Grow Sky High.

Novartis invests EUR 100 million

Sandoz plant in Schaftenau © Novartis

The subsidiary will be expanded to include, amongst other things, an integrated cell culture production, creating 190 new jobs. There originator biologicals from Novartis and biosimilars from Sandoz will be produced for the global market.

“Originator biologicals and biosimilars are the future of modern medicine. Novartis is a global leader in production and development in this field. Thanks to this investment we are even more pleased with the fact that the future of medicine will take place in Austria”, says Ard van der Meij, Country President of Novartis Austria.

Austrian quality for the world market

The Schaftenau plant is of major importance for Novelis due to the production of originator biologicals and biosimilars. This includes a focus product from Novartis pharmaceuticals for the therapy of psoriasis, psoriasis arthritis and Bektherev’s disease and two cost efficient Sandoz biosimilars. One of them is for the treatment of certain forms of blood cancer and immunological diseases, the other for the treatment of rheumatoid arthritis and other rheumatic illnesses. In 2014 and 2015, a global microparticle technology center and a state-of-the-art biologicals production for ready-to-fill syringes were open, and the production facilities were continuously expanded.

Share on Facebook Share on Facebook Share on Twitter Share on Twitter Share on Linkedin Share on Linkedin

Testimonials

Events

Meet us at events, seminars and trade shows - worldwide.

  • ABA's Open Day 2021: Austria - Your ICT and Innovation Hub in the Heart of Europe

    11 March 2021/ 09.00am + 05.00 pm, Online Conference

  • Meet us @ International Machinery Forum 2021 - The Factory of Tomorrow

    11.03 - 12.03 2021, Online Conference

Austria Map

Find the perfect location for your company

Vienna’s unique location at the heart of Europe makes it an important centre and very popular with the global pharmaceutical and biotechnology industry. Vienna is where Eastern Europe meets Western Europe. Businesses located at this international hub benefit from well-established infrastructures and highly-qualified professionals. The significant growth in the Life Sciences sector in Vienna over the last few years is an indicator of the momentum in the industry.

ABF Pharmaceutical Services

ABF Pharmaceutical Services
More testimonials

news from the business location Austria

OMV and Kommunalkredit invest in the production of green hydrogen

The Austrian oil and gas company OMV and Kommunalkredit Austria AG (Kommunalkredit) have announced a joint investment in the construction of Austria’s largest electrolysis plant to be located in the OMV Schwechat Refinery.

Evotec SE

Evotec is an active substance research company which rapidly presses ahead with innovative product approaches on the basis of development partnerships with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists.

More news All blog posts